A complete team in place
In recent months
Martin has 14 years of CMC with Lundbeck, Etienne a long history with business development at Leo Pharma and Nycomed, Louise from regulatory consulting and
Probably the best small biotech team in the world…
Trial 0204 Results (and Trial 0206 Progress)
In early March, Cessatech announced the positive result of our 0204 bioavailability trial. The primary objective of investigating drug exposure versus IV injection of approved counterparts was successful, and the trial has confirmed the primary endpoint of showing clinically relevant exposure. Additionally, CT001 has been assessed as safe and well tolerated.
Additionally, we have seen very good progress with the 0206 trial (pharmacokinetic trial in children), and we hope to have the last patient visit sometime in April or May. We will announce expected data results once we enroll the last patient. The 0205 pivotal trial is expected to begin in the second quarter, as we are still awaiting ethics committee approval.
Annual Report and Annual General Meeting
The annual report was approved during the GA
The warrant (incentive) program for key employees and management was continued, and the warrant (share) option was authorized, at a normal share price of
The journey continues….
We continue to deliver according to our plans, on our very promising asset (CT001), even if the biotech sector has seen headwinds in the stock markets lately. The fundamentals of our business have not changed. Once we have a more stable market, we will slowly increase our investor relations activities.
The year 2022 will be very interesting for the company…
For more information on
Jes Trygved, CEO
Telephone: +45 9387 2309
Email: [email protected]
(c) Decision 2022. All rights reserved., sources